SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-076333
Filing Date
2024-06-21
Accepted
2024-06-21 17:01:31
Documents
13
Period of Report
2024-06-19
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20240619.htm   iXBRL 8-K 55887
2 EX-16.1 tcrt-ex16_1.htm EX-16.1 596
3 GRAPHIC img265912089_0.jpg GRAPHIC 24111
  Complete submission text file 0000950170-24-076333.txt   214293

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20240619.xsd EX-101.SCH 32035
16 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20240619_htm.xml XML 4710
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 241061263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)